1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Sun Wants To Join The Biosimilars Party, In Time

 
• By Anju Ghangurde

India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.

competition
Sun joins fray for biosimilars • Source: Alamy

After years of watching the action from afar, India’s top-ranked drug firm Sun Pharmaceutical Industries has decided to take the plunge into the high-stakes and maturing biosimilars segment, which is now poised for take-off in key markets like the US.

Sun’s founder and managing director Dilip Shanghvi said the company was evaluating the development of products that fall into the "third wave" of biosimilars with launch timelines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products